AORT stock news · Artivion, Inc.

Stories about Artivion, Inc. (AORT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for AORT

Follow Artivion, Inc. (AORT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Nov 14, 2026, 9:09 PM ET · Opinion
Citizens JMP kept a 'Buy' rating for Artivion but lowered the price target from $48 to $42.
Neutral
Citizens JMP kept its Buy rating for Artivion but cut its price target from $48 to $42. Those mixed views leave the company's outlook unchanged.
Oct 12, 2026, 8:05 AM ET · Results
Artivion held a call to discuss its earnings for the second quarter of 2026.
Good for AORT
Artivion reported rising sales and adjusted EBITDA, won FDA approval for AMDS, and completed the Endospan deal. These gains support a stronger outlook despite lower margins and deal-related cash use.